FindTrial
Sign In

Comparative Efficacy and Safety of Tezepelumab and Dupilumab in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis

Comparative Efficacy and Safety of Tezepelumab and Dupilumab in Patients with Inadequately Controlled Asthma According to Thresholds of Type 2 Inflammatory Biomarkers: A Systematic Review and Network Meta-Analysis - Tezepelumab versus Dupilumab in asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000044672
Enrollment
1000
Registered
2021-06-28
Start date
2021-06-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

None listed

Sponsors

Showa University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients The inclusion criteria are as follows: (1) A minimum age of 12 years, (2) Inadequately controlled asthma requiring moderate-to-high doses of ICS (3) At least one episode of exacerbation in the previous year. 2. Interventions and Comparisons The NMA planned to include data for tezepelumab (210 mg, subcutaneously, once every 4 weeks), dupilumab (300 mg, subcutaneously, once every 2 weeks), benralizumab (30 mg, subcutaneously, once every 8 weeks after the first three doses administered once every 4 weeks), and mepolizumab (100 mg, subcutaneously, once every 4 weeks).

Exclusion criteria

Exclusion criteria: Patients under 12 years old Non-RCTs, phase 1, 2 or, non-phase 3 RCTs, case-control studies, and cohort studies.

Design outcomes

Primary

MeasureTime frame
Annualized exacerbation rate—

Secondary

MeasureTime frame
Change in pre-bronchodilator Fev1.0 ACQ score AQLQ score incidence of any adverse events—

Countries

Japan

Contacts

Public ContactKoichi Ando

Showa University School of Medicine Division of Respiratory Medicine and Allergology, Department of Medicine

koichi-a@med.showa-u.ac.jp03-3784-8532

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026